USFDA Accepts Biocon, Mylan's application for review of Proposed Biosimilar of Bevacizumab Medical Dialogues Bureau10 March 2020 1:15 PM ISTBiocon Ltd. and Mylan N.V. announced that the U.S. Food and Drug Administration (FDA) has accepted Mylan's Biologics License Application (BLA)...
Roche Tecentriq, Avastin combo to increase overall survival, progression-free survival in HCC Medical Dialogues Bureau22 Oct 2019 9:50 AM ISTRoche, in its recent release, in 2018, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) for Tecentriq in...
Biocon launches colon cancer drug in India, priced Rs 24,000 Ruby Khatun Khatun24 Nov 2017 10:01 AM ISTBengaluru: Biocon Ltd has launched KRABEVA, a biosimilar Bevacizumab for the treatment of patients with metastatic colorectal cancer and other types...
Intas Pharma cuts down price of cancer drug Bevacizumab by 60 percent Ruby Khatun Khatun6 Oct 2017 11:12 AM ISTAHMEDABAD: Intas Pharmaceuticals Limited, announced that the company is cutting down the cost of the cancer drug Bevacizumab by 60 percent in order to...
